Improving the cardio protective effect of aFGF in ischemic myocardium with ultrasound-mediated cavitation of heparin modified microbubbles: Preliminary experiment

Journal of Drug Targeting

Volumn 20, Issue 7, 2012, Pages 623-631

  Zhao, Ying Zheng ^a,b   Lu, Cui Tao ^a   Li, Xiao Kun ^a,b   Tang, Qin Qin ^a   Tian, Xin Qiao ^a   Zhao, Ya Ping ^a   Zhang, Yan ^c   Tian, Ji Lai ^d   Yang, Wei ^a   Ge, Shuping ^e   Nair, Chandra K ^f   Shen, Xuedong ^f  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b Zhejiang Gelusite Biology Technology Co Ltd   (China)

^c Beijing 307 Hospital   (China)

^d CHINA PHARMACEUTICAL UNIVERSITY   (China)

^e ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^f CREIGHTON UNIVERSITY CARDIAC CENTER   (United States)

Author keywords

Acidic fibroblast growth factors; Heparin modified microbubbles; Myocardial ischemia; Ultrasound mediated cavitation

Indexed keywords

EOSIN; HEMATOXYLIN; HEPARIN; RECOMBINANT ACIDIC FIBROBLAST GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ECHOCARDIOGRAPHY; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FREEZE DRYING; HEART; HEART CONTRACTION; HEART EJECTION FRACTION; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MICROBUBBLE; NONHUMAN; PRIORITY JOURNAL; RAT; ULTRASOUND;

ANIMALS; CARDIOTONIC AGENTS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ECHOCARDIOGRAPHY; FIBROBLAST GROWTH FACTOR 1; HEPARIN; INJECTIONS, INTRAVENOUS; MALE; MICROBUBBLES; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; RATS; RATS, SPRAGUE-DAWLEY; SOUND;

EID: 84863441669     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.702771     Document Type: Article

References (21)

1. Ma B, Cheng DS, Xia ZF, Ben DF, Lu W, Cao ZF, Wang Q, He J, Chai JK, Shen CA, Sun YH, Zhang GA, Hu XH. (2007). Randomized, multicenter, double-blind, and placebo-controlled trial using topical recombinant human acidic fibroblast growth factor for deep partial-thickness burns and skin graft donor site. Wound Repair Regen, 15, 795-799.
2. Cuevas P, Burgos J, Baird A. (1988). Basic fibroblast growth factor (FGF) promotes cartilage repair in vivo. Biochem Biophys Res Commun, 156, 611-618.
3. Buehler A, Martire A, Strohm C, Wolfram S, Fernandez B, Palmen M, Wehrens XH, Doevendans PA, Franz WM, Schaper W, Zimmermann R. (2002). Angiogenesis-independent cardioprotection in FGF-1 transgenic mice. Cardiovasc Res, 55, 768-777.
4. Lopez JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Thomas KA, DiSalvo J, Caputo RP, Carrozza JP, Douglas PS, Sellke FW, Simons M. (1998). Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. Am J Physiol, 274, H930-H936.
5. Koch A, Palchyk E, Gassler N, Dengler TJ, Remppis A, Pritsch M, Sack FU, Hagl S, Schnabel PA. (2006). Expression of plateletderived growth factor and fibroblast growth factor in cryopreserved endomyocardial biopsies early and late after heart transplant. Ann Thorac Surg, 81, 1372-1378.
6. Pagonopoulou O, Efthimiadou A, Lambropoulou M, Papadopoulos N, Nikolettos NK. (2008). Erythropoietin and growth factors exhibit differential angiogenic potential in mouse heart. In Vivo, 22, 587-591.
7. Pye DA, Vivès RR, Hyde P, Gallagher JT. (2000). Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. Glycobiology, 10, 1183-1192.
8. Angulo J, Ojeda R, de Paz JL, Lucas R, Nieto PM, Lozano RM, Redondo-Horcajo M, Giménez-Gallego G, Martín-Lomas M. (2004). The activation of fibroblast growth factors (FGFs) by glycosaminoglycans: influence of the sulfation pattern on the biological activity of FGF-1. Chembiochem, 5, 55-61.
9. Liu Y, Miyoshi H, Nakamura M. (2006). Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery. J Control Release, 114, 89-99.
10. Tian JL, Zhao YZ, Jin Z, Lu CT, Tang QQ, Xiang Q, Sun CZ, Zhang L, Xu YY, Gao HS, Zhou ZC, Li XK, Zhang Y. (2010). Synthesis and characterization of Poloxamer 188-grafted heparin copolymer. Drug Dev Ind Pharm, 36, 832-838.
11. Zhao YZ, Sun CZ, Lu CT, Dai DD, Lv HF, Wu Y, Wan CW, Chen LJ, Lin M, Li XK. (2011). Characterization and anti-tumor activity of chemical conjugation of doxorubicin in polymeric micelles (DOXP) in vitro. Cancer Lett, 311, 187-194.
12. Schneider M. (1999). SonoVue, a new ultrasound contrast agent. Eur Radiol, 9 Suppl 3, S347-S348.
13. Farook U, Stride E, Edirisinghe M. Controlling the size and size distribution of electrohydrodynamically prepared microbubbles. J Bubble Sci Eng Tech, 2009,1:53-57.
14. Correas JM, Tranquart F, Claudon M. Guidelines for contrast enhanced ultrasound (CEUS) - update 2008. J Radiol. 2009;90:123- 138; quiz 139-140.
15. Shimoni S, Frangogiannis NG, Aggeli CJ, Shan K, Quinones MA, Espada R, Letsou GV, Lawrie GM, Winters WL, Reardon MJ, Zoghbi WA. (2002). Microvascular structural correlates of myocardial contrast echocardiography in patients with coronary artery disease and left ventricular dysfunction: implications for the assessment of myocardial hibernation. Circulation, 106, 950-956.
16. Temporelli P, Cioffi G, Dini F, Ghio S, Rossi A. Role of echocardiography in the tailored follow-up of outpatients with chronic heart failure. Giornale italiano di cardiologia, 2006; 11: 24S-32S.
17. Kaufmann BA, Lindner JR. (2007). Molecular imaging with targeted contrast ultrasound. Curr Opin Biotechnol, 18, 11-16.
18. Walton CB, Anderson CD, Boulay R, Shohet RV. (2011). Introduction to the ultrasound targeted microbubble destruction technique. J Vis Exp, Jun 12;(52). pii: 2963. doi: 10.3791/2963.
19. Bekeredjian R, Katus HA, Kuecherer HF. (2006). Therapeutic use of ultrasound targeted microbubble destruction: a review of noncardiac applications. Ultraschall Med, 27, 134-140.
20. Lu CT, Zhao YZ, Wu Y, Tian XQ, Li WF, Huang PT, Li XK, Sun CZ, Zhang L. (2011). Experiment on enhancing antitumor effect of intravenous epirubicin hydrochloride by acoustic cavitation in situ combined with phospholipid-based microbubbles. Cancer Chemother Pharmacol, 68, 343-348.
21. Bekeredjian R, Kuecherer HF, Kroll RD, Katus HA, Hardt SE. (2007). Ultrasound-targeted microbubble destruction augments protein delivery into testes. Urology, 69, 386-389.